这是一篇来自已证抗体库的有关人类 MSH6的综述,是根据21篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合MSH6 抗体。
MSH6 同义词: GTBP; GTMBP; HNPCC5; HSAP; p160

赛默飞世尔
小鼠 单克隆(44)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH6抗体(Zymed, 08-1374)被用于被用于免疫组化-石蜡切片在人类样本上. BMC Surg (2014) ncbi
小鼠 单克隆(44)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH6抗体(Zymed, 44)被用于被用于免疫组化-石蜡切片在人类样本上. Hum Pathol (2011) ncbi
小鼠 单克隆(44)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH6抗体(Zymed, 44)被用于被用于免疫组化-石蜡切片在人类样本上. Fam Cancer (2010) ncbi
小鼠 单克隆(44)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH6抗体(Zymed, 44)被用于被用于免疫组化-石蜡切片在人类样本上. Gynecol Oncol (2009) ncbi
小鼠 单克隆(44)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MSH6抗体(Zymed Laboratories, 44)被用于被用于免疫组化-石蜡切片在人类样本上. APMIS (2008) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 单克隆(EPR3945)
  • 免疫印迹; 人类; 图 e8k
艾博抗(上海)贸易有限公司 MSH6抗体(Abcam, ab92471)被用于被用于免疫印迹在人类样本上 (图 e8k). Nature (2019) ncbi
西格玛奥德里奇
  • 免疫细胞化学; 人类
西格玛奥德里奇 MSH6抗体(Ventana, 790-4455)被用于被用于免疫细胞化学在人类样本上. Int J Cancer (2015) ncbi
丹科医疗器械技术服务(上海)有限公司
domestic rabbit 单克隆(EP49)
  • 免疫组化-石蜡切片; 人类; 图 1
丹科医疗器械技术服务(上海)有限公司 MSH6抗体(Dako, IR086)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1). Cancer Manag Res (2020) ncbi
domestic rabbit 单克隆(EP49)
  • 免疫组化; 人类; 1:1000; 图 1f
丹科医疗器械技术服务(上海)有限公司 MSH6抗体(Dako, EP49)被用于被用于免疫组化在人类样本上浓度为1:1000 (图 1f). PLoS ONE (2020) ncbi
domestic rabbit 单克隆(EP49)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 1
丹科医疗器械技术服务(上海)有限公司 MSH6抗体(Dako, M3646)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (表 1). Br J Cancer (2016) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(D60G2)
  • 免疫印迹基因敲除验证; 人类; 1:1000; 图 s1b
  • 免疫印迹; 人类; 1:1000; 图 s1b
赛信通(上海)生物试剂有限公司 MSH6抗体(Cell Signaling, D60G2)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:1000 (图 s1b) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 s1b). Nat Commun (2018) ncbi
domestic rabbit 单克隆(D60G2)
  • 免疫印迹; 人类; 图 s1
赛信通(上海)生物试剂有限公司 MSH6抗体(Cell Signaling, 5424)被用于被用于免疫印迹在人类样本上 (图 s1). Proc Natl Acad Sci U S A (2016) ncbi
碧迪BD
小鼠 单克隆(44/MSH6)
  • 免疫组化-石蜡切片; 人类; 表 2
碧迪BD MSH6抗体(BD Transduction Laboratories, 44/MSH6)被用于被用于免疫组化-石蜡切片在人类样本上 (表 2). Am J Surg (2017) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫印迹基因敲除验证; 小鼠; 1:1000; 图 4
碧迪BD MSH6抗体(BD Biosciences, 610918)被用于被用于免疫印迹基因敲除验证在小鼠样本上浓度为1:1000 (图 4). PLoS Genet (2016) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫组化; 人类; 1:800; 图 s4b
碧迪BD MSH6抗体(BD Biosciences, 610919)被用于被用于免疫组化在人类样本上浓度为1:800 (图 s4b). Nat Med (2016) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫组化; 人类; 1:100
碧迪BD MSH6抗体(BD Pharmingen, 44)被用于被用于免疫组化在人类样本上浓度为1:100. JAMA Oncol (2016) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫印迹; 小鼠; 1:2500; 图 4a
碧迪BD MSH6抗体(BD Biosciences, 610918)被用于被用于免疫印迹在小鼠样本上浓度为1:2500 (图 4a). DNA Repair (Amst) (2016) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫组化; 人类; 1:200
碧迪BD MSH6抗体(BD Transduction Laboratories, 44/MSH6)被用于被用于免疫组化在人类样本上浓度为1:200. Virchows Arch (2015) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫组化-石蜡切片; 人类
碧迪BD MSH6抗体(BD Pharmingen, 610919)被用于被用于免疫组化-石蜡切片在人类样本上. Cancer Genet (2014) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫组化; 人类; 1:100; 图 1
碧迪BD MSH6抗体(BD Biosciences, 44/MSH6)被用于被用于免疫组化在人类样本上浓度为1:100 (图 1). Cancer Genet (2013) ncbi
小鼠 单克隆(44/MSH6)
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
碧迪BD MSH6抗体(BD Bioscience, 610919)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. PLoS ONE (2013) ncbi
文章列表
  1. Shao W, Wang C, Wang L, Xiao F, Xiao D, Yang H, et al. A Hereditable Mutation of MSH2 Gene Associated with Lynch Syndrome in a Five Generation Chinese Family. Cancer Manag Res. 2020;12:1469-1482 pubmed 出版商
  2. Rübben A, Wahl R, Eggermann T, Dahl E, Ortiz Brüchle N, Cacchi C. Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype. PLoS ONE. 2020;15:e0230003 pubmed 出版商
  3. Wang J, Liu Y, Liu Y, Zheng S, Wang X, Zhao J, et al. Time-resolved protein activation by proximal decaging in living systems. Nature. 2019;569:509-513 pubmed 出版商
  4. Zou X, Owusu M, Harris R, Jackson S, Loizou J, Nik Zainal S. Validating the concept of mutational signatures with isogenic cell models. Nat Commun. 2018;9:1744 pubmed 出版商
  5. Massalou D, Benizri E, Chevallier A, Duranton Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213:377-387 pubmed 出版商
  6. Zhao X, Lokanga R, Allette K, Gazy I, Wu D, Usdin K. A MutS?-Dependent Contribution of MutS? to Repeat Expansions in Fragile X Premutation Mice?. PLoS Genet. 2016;12:e1006190 pubmed 出版商
  7. Hrecka K, Hao C, Shun M, Kaur S, Swanson S, Florens L, et al. HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins. Proc Natl Acad Sci U S A. 2016;113:E3921-30 pubmed 出版商
  8. Park J, Powell A, Roxburgh C, Horgan P, McMillan D, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114:562-70 pubmed 出版商
  9. Beltran H, Prandi D, Mosquera J, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298-305 pubmed 出版商
  10. Taieb J, Zaanan A, Le Malicot K, Julie C, Blons H, Mineur L, et al. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. JAMA Oncol. 2016;2:643-653 pubmed 出版商
  11. Fischer J, Dudley S, Miller A, Liskay R. An intact Pms2 ATPase domain is not essential for male fertility. DNA Repair (Amst). 2016;39:46-51 pubmed 出版商
  12. Vanoli A, Argenti F, Vinci A, La Rosa S, Viglio A, Riboni R, et al. Hepatoid carcinoma of the pancreas with lymphoid stroma: first description of the clinical, morphological, immunohistochemical, and molecular characteristics of an unusual pancreatic carcinoma. Virchows Arch. 2015;467:237-45 pubmed 出版商
  13. Vilar E, Mork M, Cuddy A, Borràs E, Bannon S, Taggart M, et al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014;207:495-502 pubmed 出版商
  14. Gargalionis A, Korkolopoulou P, Farmaki E, Piperi C, Dalagiorgou G, Adamopoulos C, et al. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer. 2015;136:1515-27 pubmed 出版商
  15. Baiocchi G, Portolani N, Vermi W, Baronchelli C, Gheza F, Zogno C, et al. Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. BMC Surg. 2014;14:9 pubmed 出版商
  16. Dadone B, Ambrosetti D, Carpentier X, Duranton Tanneur V, Burel Vandenbos F, Amiel J, et al. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?. Cancer Genet. 2013;206:347-52 pubmed
  17. Gupte M, Tuck A, Sharma V, Williams K. Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. PLoS ONE. 2013;8:e74071 pubmed 出版商
  18. Gatalica Z, Lilleberg S, Monzon F, Koul M, Bridge J, Knezetic J, et al. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes. Hum Pathol. 2011;42:1979-88 pubmed 出版商
  19. Cossio S, Koehler Santos P, Pessini S, Mónego H, Edelweiss M, Meurer L, et al. Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil. Fam Cancer. 2010;9:131-9 pubmed 出版商
  20. Arabi H, Guan H, Kumar S, Cote M, Bandyopadhyay S, Bryant C, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol. 2009;113:153-8 pubmed 出版商
  21. Mylona E, Zarogiannos A, Nomikos A, Giannopoulou I, Nikolaou I, Zervas A, et al. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder. APMIS. 2008;116:59-65 pubmed 出版商